^
Association details:
| Biomarker: | EGFR L718Q |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | JIN-A02 (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
MA07.08 - JIN-A02, a Highly Effective 4th Generation EGFR-TKI, Targeting EGFR C797S Triple Mutation in NSCLC
Published date:
07/12/2022
Excerpt:
These preclinical studies demonstrated that JIN-A02 is a potential best-in-class fourth-generation EGFR TKI with high potency and selectivity. JIN-A02 showed robust activities against EGFR C797S mutation including single and double EGFR mutations. It was also effective against L718Q, for which there are currently no treatment alternatives.
